
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter. In Q4, Ionis Pharmaceuticals earned $224.61 million, and total sales reached $440.00 million.